Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …

Defective DNA mismatch repair (dMMR) is associated with many cancer types including
colon, gastric, endometrial, ovarian, hepatobiliary tract, urinary tract, brain and skin cancers …

Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch
repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients …

The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …

Importance Only 1 randomized clinical trial has shown the superiority of immune checkpoint
inhibitors in patients with deficient mismatch repair and/or microsatellite instability …

Simple Summary YAP/TAZ are the central effectors of the Hippo pathway and orchestrate
their oncogenic program by binding to TEAD transcriptional factors. Here, we document a …

Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd),
often respond to immune checkpoint blockade therapies, while those with mismatch repair …